xconomy on alny/silence at asco , page-14

?We believe the results from our ALN-VSP Phase I trial represent an important milestone in the advancement of RNAi therapeutics. Indeed, our data demonstrate for the first time both clinical activity and RNAi mechanism for an RNAi therapeutic,? said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. ?Clearly, these data are not only important for the continued advancement of our ALN-VSP program, but they also significantly increase our confidence in our entire pipeline of systemically delivered RNAi therapeutics, including ALN-TTR01 which is in a Phase I study for the treatment of transthyretin mediated amyloidosis, and ALN-PCS, which will soon enter clinical trials for the treatment of severe hypercholesterolemia.?

http://au.finance.yahoo.com/news/Alnylam-Presents-Phase-I-Data-bw-2803675668.html?x=0